Author

M. E. Gleave

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Research Focus:gene regulatory network inference· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Assay:bulk RNA-seq· 2 Research Focus:chromatin & epigenetic regulation· 2

Frequent Co-Authors

L. Fazli· 4 shared A. Blomme· 2 shared B. McConeghy· 2 shared C. Nixon· 2 shared C. Ntala· 2 shared D. Sumpton· 2 shared F. Hach· 2 shared F. Zhang· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

L. Fazli

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

ABI1 regulates transcriptional activity of Androgen Receptor by novel DNA and AR binding mechanism

B. A. Porter, X. Li, N. Arya, F. Zhang, S. H. Y. Kung, L. Fazli, H. Zarni Oo, Y. Li, K. Marincin, K. Kukkonen, H. Urhonen, M. A. Ortiz, A. P. Kemraj, E. Corey, X. Dong, , L. Kotula

This paper identifies ABI1 as an epigenetic regulator of transcriptional homeostasis in AR-driven cancers through novel DNA and AR binding mechanisms.

bioRxiv · May 26, 2023 · PreprintCancer Biology

THEM6-mediated lipid remodelling sustains stress resistance in cancer

A. Blomme, C. Peter, E. Mui, G. Rodriguez Blanco, L. M. Mason, L. E. Jamieson, G. H. McGregor, S. Lilla, C. Ntala, R. Patel, M. Thiry, S. H. Kung, C. A. Ford, L. K. Rushworth, D. J. McGarry, , H. Y. Leung

This study identifies THEM6 as a marker of ADT resistance in prostate cancer, showing its role in lipid homeostasis and stress response, and highlights it as a potential therapeutic target.

bioRxiv · Apr 4, 2021Cancer Biology

Dynamic phase separation of the androgen receptor and its coactivators to regulate gene expression.

F. Zhang, S. Wong, J. Lee, S. Lingadahalli, C. Wells, N. Saxena, C. Sanchez, B. Sun, A. K. Parra-Nunez, N. Chan, J. M. Bui, Y. Wang, P. S. Rennie, N. A. Lack, A. Cherkasov, , N. Lallous

This study shows that androgen receptor (AR) and its co-activator MED1 form dynamic, AR-rich condensates at superenhancers in prostate cancer, which are crucial for oncogenic gene expression.

bioRxiv · Mar 27, 2021Cancer Biology

Schlafen family member 5 (SLFN5) regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer

R. S. Martinez, M. J. Salji, L. Rushworth, C. Ntala, G. Rodriguez Blanco, A. Hedley, W. Clark, P. Peixoto, E. Hervouet, E. Renaude, S. H. Kung, L. C. Galbraith, C. Nixon, S. Lilla, G. M. MacKay, , H. Y. Leung

This study identifies SLFN5 as an AR-regulated biomarker in CRPC that promotes tumour growth by regulating LAT1-mediated mTOR activation.

bioRxiv · Sep 17, 2020 · PreprintCancer Biology

Functional mapping of androgen receptor enhancer activity

C.-C. F. Huang, S. Lingadahalli, T. Morova, D. Ozturan, E. Hu, I. P. L. Yu, S. Linder, M. Hoogstraat, S. Stelloo, F. Sar, H. van der Poel, U. B. Altintas, M. Saffarzadeh, S. Le Bihan, B. McConeghy, , N. A. Lack

The paper functionally maps AR enhancer activity using STARRseq, finding most AR binding sites are inactive or constitutively active, with inducible enhancers forming regulatory hubs that drive gene transcription.

bioRxiv · Aug 18, 2020Cancer Biology

BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma

R. Shrestha, N. Nabavi, Y.-Y. Lin, F. Mo, S. Anderson, S. Volik, H. H. Adomat, D. Lin, H. Xue, X. Dong, R. Shukin, R. H. Bell, B. McConeghy, A. Haegert, S. Brahmbhatt, , C. C. Collins

The paper identifies BAP1 loss as a marker for a distinct immunogenic PeM subtype, suggesting potential therapeutic targets like immune checkpoint inhibitors.

bioRxiv · Dec 13, 2018Cancer Biology